IP Library Granted Patent US 9,358,243
Granted Patent B2
US 9,358,243 · App. 14/347,649 · Granted Jun 7, 2016

Pharmaceutical compounds for use in the therapy of

Inventors: Bastien Castagner (Zurich, CH); Jean-Christophe Leroux (Zurich, CH); Mattias Ivarsson (Zurich, CH); Gisbert Schneider (Zurich, CH); Anna Pratsinis (Zurich, CH)
Assignee: ETH ZURICH
A61K31/6615A61K31/185A61K31/255A61K31/4164A61K31/7048A61K38/14A61K45/06C07C305/20C07F9/093C07F9/117
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,358,243
App. No.
14/347,649
Granted
Jun 7, 2016
Kind
B2
Abstract

The invention relates to a compound described by a general formula (1), wherein each X independently can be OPO 3 2− , OPSO 2 2− or OSO 3 − ; R 1 comprises a solubility function such as a polyethylene glycol moiety and each X independently can be OPO 3 2− , OPSO 2 2− , − or OSO 3 − ; and Z is an alkyl chain comprising 1 to 3 carbon and/or hetero atoms. The invention further relates to polysulfate derivatives or mixed polyphosphate/sulphate derivatives of six-membered cyclic polyols for use in the therapy of infection by Clostridium difficile.

Claims (13)

1. A method for treating a C. difficile infection, comprising administering to a subject a composition comprising a compound described by general formula (16a) or (16b):

wherein

a) X 2 is OSO 3 − , and X 1 , X 3 , X 4 , X 5 and X 6 are each independently selected from OPO 3 2− , OPSO 2 2− or OSO 3 − ;

b) X 1 , X 3 and X 5 are OPO 3 2− and X 2 , X 4 and X 6 are OSO 3 −

c) X 1 , X 3 and X 5 are OSO 3 − and X 2 , X 4 and X 6 are OPO 3 2−

d) X 4 , X 5 and X 6 are OSO 3 − and X 1 , X 2 and X 3 are OPO 3 2− ,

e) X 4 , X 5 and X 6 are OPO 3 2− and X 1 , X 2 and X 3 are OSO 3 − or

f) X 2 and X 5 are OPO 3 2− and X 1 , X 3 , X 4 , and X 6 are OSO 3 − ,

g) X 2 and X 5 are OSO 3 − and X 1 , X 3 , X 4 , and X 6 are OPO 3 2− ,

h) X 2 and X 3 are OPO 3 2− and X 1 , X 4 , X 5 , and X 6 are OSO 3 − , or

i) X 2 and X 3 are OSO 3 − and X 1 , X 4 , X 5 , and X 6 are OPO 3 2− .

2. The method of claim 1 , wherein the composition further comprises an antibiotic.

3. The method of claim 2 , wherein the antibiotic is metronidazole, vancomycin or fidaxomicin.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 2, 2014
From: CASTAGNER, BASTIEN; LEROUX, JEAN- CHRISTOPHE; IVARSSON, MATTIAS; SCHNEIDER, GISBERT; PRATSINIS, ANNA
To: ETH ZURICH
Reel/Frame 032577/0880 →
Priority Claims (2)
EP 11007933 · Sep 29, 2011 · regional
EP 11007935 · Sep 29, 2011 · regional
Continuity (1)
Related Publication 20140235590A1 · Aug 21, 2014